GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Scaled Net Operating Assets

Regenicin (Regenicin) Scaled Net Operating Assets : -1.48 (As of Mar. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regenicin's operating assets for the quarter that ended in Mar. 2023 was $0.00 Mil. Regenicin's operating liabilities for the quarter that ended in Mar. 2023 was $17.43 Mil. Regenicin's Total Assets for the quarter that ended in Dec. 2022 was $11.79 Mil. Therefore, Regenicin's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2023 was -1.48.


Regenicin Scaled Net Operating Assets Historical Data

The historical data trend for Regenicin's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Scaled Net Operating Assets Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.13 -58.54 -742.60 -1,089.75 -994.00

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -777.00 -1,203.50 -2,485.00 -1,135.07 -1.48

Competitive Comparison of Regenicin's Scaled Net Operating Assets

For the Biotechnology subindustry, Regenicin's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Regenicin's Scaled Net Operating Assets falls into.



Regenicin Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regenicin's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Sep. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Sep. 2022 )
=(Operating Assets (A: Sep. 2022 )-Operating Liabilities (A: Sep. 2022 ))/Total Assets (A: Sep. 2021 )
=(0-4.97)/0.005
=-994.00

where

Operating Assets(A: Sep. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.015 - 0.015
=0

Operating Liabilities(A: Sep. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=5.613 - 0 - 0.643
=4.97

Regenicin's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2023 )
=(Operating Assets (Q: Mar. 2023 )-Operating Liabilities (Q: Mar. 2023 ))/Total Assets (Q: Dec. 2022 )
=(0-17.427)/11.794
=-1.48

where

Operating Assets(Q: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=11.859 - 11.859
=0

Operating Liabilities(Q: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=18.07 - 0 - 0.643
=17.427

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenicin Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Regenicin's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenicin (Regenicin) Business Description

Industry
Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines